145 related articles for article (PubMed ID: 24835677)
21. Expression and purification of functional human mu opioid receptor from E.coli.
Ma Y; Kubicek J; Labahn J
PLoS One; 2013; 8(2):e56500. PubMed ID: 23437147
[TBL] [Abstract][Full Text] [Related]
22. The bovine mu-opioid receptor: cloning of cDNA and pharmacological characterization of the receptor expressed in mammalian cells.
Onoprishvili I; Andria ML; Vilim FS; Hiller JM; Simon EJ
Brain Res Mol Brain Res; 1999 Nov; 73(1-2):129-37. PubMed ID: 10581406
[TBL] [Abstract][Full Text] [Related]
23. Selectivity of mu-opioid receptor determined by interfacial residues near third extracellular loop.
Bonner G; Meng F; Akil H
Eur J Pharmacol; 2000 Sep; 403(1-2):37-44. PubMed ID: 10969141
[TBL] [Abstract][Full Text] [Related]
24. Mutation of human mu opioid receptor extracellular "disulfide cysteine" residues alters ligand binding but does not prevent receptor targeting to the cell plasma membrane.
Zhang P; Johnson PS; Zöllner C; Wang W; Wang Z; Montes AE; Seidleck BK; Blaschak CJ; Surratt CK
Brain Res Mol Brain Res; 1999 Oct; 72(2):195-204. PubMed ID: 10529478
[TBL] [Abstract][Full Text] [Related]
25. Functional role of a conserved motif in TM6 of the rat mu opioid receptor: constitutively active and inactive receptors result from substitutions of Thr6.34(279) with Lys and Asp.
Huang P; Li J; Chen C; Visiers I; Weinstein H; Liu-Chen LY
Biochemistry; 2001 Nov; 40(45):13501-9. PubMed ID: 11695897
[TBL] [Abstract][Full Text] [Related]
26. Computational insights into the G-protein-biased activation and inactivation mechanisms of the μ opioid receptor.
Cheng JX; Cheng T; Li WH; Liu GX; Zhu WL; Tang Y
Acta Pharmacol Sin; 2018 Jan; 39(1):154-164. PubMed ID: 29188799
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and evaluation of a ligand targeting the μ and δ opioid receptors for drug delivery to lung cancer.
Li G; Low PS
Bioorg Med Chem Lett; 2017 May; 27(9):2074-2078. PubMed ID: 28291693
[TBL] [Abstract][Full Text] [Related]
28. Complex of an active mu-opioid receptor with a cyclic peptide agonist modeled from experimental constraints.
Fowler CB; Pogozheva ID; Lomize AL; LeVine H; Mosberg HI
Biochemistry; 2004 Dec; 43(50):15796-810. PubMed ID: 15595835
[TBL] [Abstract][Full Text] [Related]
29. Molecular characteristics of IgA and IgM Fc binding to the Fcalpha/muR.
Cho Y; Usui K; Honda S; Tahara-Hanaoka S; Shibuya K; Shibuya A
Biochem Biophys Res Commun; 2006 Jun; 345(1):474-8. PubMed ID: 16681999
[TBL] [Abstract][Full Text] [Related]
30. K303⁶·⁵⁸ in the μ opioid (MOP) receptor is important in conferring selectivity for covalent binding of β-funaltrexamine (β-FNA).
DiMattio KM; Chen C; Shi L; Liu-Chen LY
Eur J Pharmacol; 2015 Feb; 748():93-100. PubMed ID: 25481857
[TBL] [Abstract][Full Text] [Related]
31. Truncated G protein-coupled mu opioid receptor MOR-1 splice variants are targets for highly potent opioid analgesics lacking side effects.
Majumdar S; Grinnell S; Le Rouzic V; Burgman M; Polikar L; Ansonoff M; Pintar J; Pan YX; Pasternak GW
Proc Natl Acad Sci U S A; 2011 Dec; 108(49):19778-83. PubMed ID: 22106286
[TBL] [Abstract][Full Text] [Related]
32. Determination of the amino acid residue involved in [3H]beta-funaltrexamine covalent binding in the cloned rat mu-opioid receptor.
Chen C; Yin J; Riel JK; DesJarlais RL; Raveglia LF; Zhu J; Liu-Chen LY
J Biol Chem; 1996 Aug; 271(35):21422-9. PubMed ID: 8702924
[TBL] [Abstract][Full Text] [Related]
33. Isolating and characterizing three alternatively spliced mu opioid receptor variants: mMOR-1A, mMOR-1O, and mMOR-1P.
Xu J; Xu M; Bolan E; Gilbert AK; Pasternak GW; Pan YX
Synapse; 2014 Apr; 68(4):144-52. PubMed ID: 24375714
[TBL] [Abstract][Full Text] [Related]
34. Crystal structure of biphalin sulfate: a multireceptor opioid peptide.
Flippen-Anderson JL; Deschamps JR; George C; Hruby VJ; Misicka A; Lipkowski AW
J Pept Res; 2002 Mar; 59(3):123-33. PubMed ID: 11985706
[TBL] [Abstract][Full Text] [Related]
35. Comparison of the amino acid residues in the sixth transmembrane domains accessible in the binding-site crevices of mu, delta, and kappa opioid receptors.
Xu W; Li J; Chen C; Huang P; Weinstein H; Javitch JA; Shi L; de Riel JK; Liu-Chen LY
Biochemistry; 2001 Jul; 40(27):8018-29. PubMed ID: 11434771
[TBL] [Abstract][Full Text] [Related]
36. Exploring the structure of opioid receptors with homology modeling based on single and multiple templates and subsequent docking: a comparative study.
Bera I; Laskar A; Ghoshal N
J Mol Model; 2011 May; 17(5):1207-21. PubMed ID: 20661609
[TBL] [Abstract][Full Text] [Related]
37. Beta-[3H]funaltrexamine-labeled mu-opioid receptors: species variations in molecular mass and glycosylation by complex-type, N-linked oligosaccharides.
Liu-Chen LY; Chen C; Phillips CA
Mol Pharmacol; 1993 Oct; 44(4):749-56. PubMed ID: 8232225
[TBL] [Abstract][Full Text] [Related]
38. Molecular docking reveals a novel binding site model for fentanyl at the mu-opioid receptor.
Subramanian G; Paterlini MG; Portoghese PS; Ferguson DM
J Med Chem; 2000 Feb; 43(3):381-91. PubMed ID: 10669565
[TBL] [Abstract][Full Text] [Related]
39. -mu opiate receptor. Charged transmembrane domain amino acids are critical for agonist recognition and intrinsic activity.
Surratt CK; Johnson PS; Moriwaki A; Seidleck BK; Blaschak CJ; Wang JB; Uhl GR
J Biol Chem; 1994 Aug; 269(32):20548-53. PubMed ID: 8051154
[TBL] [Abstract][Full Text] [Related]
40. Opioid receptor three-dimensional structures from distance geometry calculations with hydrogen bonding constraints.
Pogozheva ID; Lomize AL; Mosberg HI
Biophys J; 1998 Aug; 75(2):612-34. PubMed ID: 9675164
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
